On November 16, 2009, Integra LifeSciences Holdings Corporation announced that it will suspend the enrollment of new patients in the clinical trial for DuraGen Plus� Adhesion Barrier Matrix for evaluating the safety and effectiveness as an adhesion barrier in spinal surgery. As previously announced, the Company, through its study contract research organization, conducted an interim analysis of the results of the clinical trial to date. The analysis concluded that a significantly larger number of patients than originally planned for in the current protocol would be necessary to demonstrate a statistically significant difference between the control arm (surgery alone) and the study arm (DuraGen Plus� Adhesion Barrier Matrix) for either of the two primary endpoints, pain/functional outcomes and the formation of scar as determined by magnetic resonance imaging (MRI). Accordingly, the Company has suspended recruitment and enrollment of new patients into the trial. The Company is working with the U.S. Food and Drug Administration (FDA) to determine the extent to which the trial will continue for patients already enrolled, and with the investigators to determine the potentially significant scientific value in data developed in the trial to date. The safety profile of the DuraGen� product was well-characterized during the study, and safety considerations played no part in the decision to suspend new enrollment in the clinical trial. This result does not disprove the fundamental science behind the collagen matrix technology, which is known to suppress the scar response. After the Company has completed the necessary requirements and obligations for the trial in accordance with FDA regulations and requirements and the requirements of the investigators and their governing Institutional Review Boards (IRBs), and in the interests of science, it will consider other possible studies to prove the effectiveness of its collagen matrix technology for this, or related indications. The DuraGen Dural Regeneration Matrix family of products has been used in over 750,000 patients as dural replacements in the cranium and spine.

Integra LifeSciences Holdings Corp. reported unaudited consolidated financial results for the third quarter ended September 30, 2009. Total revenues were $172.3 million, reflecting an increase of $5.3 million, or 3%, over the third quarter of 2008. Excluding the impact of currency exchange rates, revenues increased 4%. The company reported GAAP net income of $14.4 million, or $0.49 per diluted share, for the third quarter of 2009, compared to GAAP net loss of $16.9 million, or a loss of $0.60 per diluted share, for the third quarter of 2008. Adjusted net income for the third quarter of 2009 was $15.6 million, or $0.53 per diluted share. Adjusted net income for the third quarter of 2008 was $13.3 million, or $0.45 per diluted share. Integra generated $28.4 million in cash flows from operations and used $5.7 million of cash on capital expenditures in the third quarter of 2009. Adjusted EBITDA for the third quarter of 2009 was $34.9 million, an increase of 11% compared to the same period last year. Adjusted EBITDA excluding stock-based compensation for the third quarter of 2009 was $38.7 million, an increase of 12% compared to the same period last year. For the third quarter of 2009, adjusted net income excluding intangible asset amortization was $18.8 million, or $0.64 per diluted share. Adjusted net income excluding intangible asset amortization for the third quarter of 2008 was $16.4 million, or $0.56 per diluted share. Operating income was $23.8 million against operating loss of $22.9 million a year ago. Income before income taxes was $18.1 million against loss of $29.9 million a year ago. The company is updating its GAAP earnings per share guidance and reiterating its revenue and adjusted earnings per share guidance for the full year 2009. The company continues to anticipate revenues between $680 million and $700 million. The company is guiding to GAAP earnings per diluted share of between $1.59 and $1.79 and to adjusted earnings per diluted share of between $2.00 and $2.20. The company expects GAAP net income in the range of $46.9 million to $52.9 million. The company expects adjusted net income in the range of $59 million to $65 million. The company expects GAAP diluted net income per share in the range of $1.59 to $1.79.

On November 3, 2009, the Board of Directors of Integra LifeSciences Holdings Corporation amended the Company's Bylaws to provide a more detailed process for business brought before meetings of stockholders, including procedures and disclosures for stockholders submitting proposals or nominating directors. These procedures include a specified time period for stockholders to propose business or to make nominations at annual meetings (generally, between 90 and 120 days before the one-year anniversary of the Company's prior year's annual meeting date). Other technical changes to other bylaw provisions were adopted to be consistent with prevalent practices at other companies.